Tagged With Alzheimer’s

The FDA approved a controversial, $56,000-a-year Alzheimer's drug despite opposition inside the agency, internal memos show


A third member of a prestigious FDA panel has resigned over the approval of a controversial new Alzheimer's drug


The 9 biotechs that stand to win after the FDA took a new approach to approving Biogen's Alzheimer's drug



The FDA approved a drug to treat the underlying cause of Alzheimer's and potentially slow its progression. But not all doctors are willing to prescribe it.


Biogen jumps 6% ahead of a key FDA decision for its Alzheimer's drug


Eli Lilly falls 9% after its Alzheimer's drug data underwhelms Wall Street



Biogen plummets 32% after its Alzheimer's therapy fails to win support from FDA advisory committee


A $44 billion biotech just got some good news from the FDA about a key Alzheimer's drug, and the stock is soaring


Scientists have created an Alzheimer's blood test that could be available within a few years


Morgan Stanley double-upgrades Biogen and says the stock can surge another 30%


Trump keeps boasting he 'aced' a 'very hard' cognitive test: Here's one like it you can take — see if you can match him


Trump mocked his father as he started succumbing to Alzheimer's, according to his niece's upcoming tell-all



B. Smith, influential model, TV host, and restaurateur died at 70 after battle with early onset Alzheimer's disease


People who grow up in the South are more likely to have worse brain health in later life, even if they move away as a teen


Living with an optimistic partner may lower your risk of dementia


Eating lots of trans fats like packaged doughnuts and margarine could make you 75% more likely to get Alzheimer's



High blood pressure could make your brain shrink over time, according to new research


A drug for treating prostate cancer has been linked with increased risk of dementia, study finds


Bill Gates says there could be a way to predict Alzheimer’s using a voice app that listens for 'warning signs'


Your multivitamins and brain-boosting pills may be suspect, and regulators are cracking down on the $40 billion industry